AI Brings Personalized Medicine Closer to Reality, Offering New Hope for Rare Cancer Patients
Artificial intelligence is enabling doctors to move beyond average-based treatment protocols and tailor care to individual patients, a shift with profound implications for those whose conditions fall outside the norm.
Artificial intelligence is beginning to transform medicine from a field that treats the average patient to one that can tailor care to the individual, offering new hope for people whose conditions fall outside the norm. The shift is driven by AI's ability to extract patterns from medical data that humans cannot easily see, and it is already producing results in cancer detection and treatment planning.
The limitations of the current approach are well known. Medical knowledge is built on randomized controlled trials that compare groups of patients, and the results are averages. As researchers have pointed out, an average effect can mask a wide distribution: substantial benefits for some, little benefit for many, and harm for a few. Because most treatments are designed for the average patient, they rarely work for everyone, and they work better for some than others. For patients whose biology does not match the average, this can mean months spent on a treatment that was never going to help, while their disease advances.
The cost of treating an individual as an average is not just ineffective care. It is also unnecessary suffering and lost time. For young patients with diseases that typically affect older people, the problem is especially acute. Multiple myeloma, a cancer of plasma cells in the bone marrow, has an average age of diagnosis of 69, and fewer than 1% of patients are younger than 35. Young myeloma patients are underrepresented in research, so much of what is known about the disease comes from older populations. Treatment protocols and survival estimates for younger patients are therefore drawn largely from groups they do not belong to.
AI offers a way out of this trap by helping to understand the individual patient, choose a treatment based on that understanding, and even build new treatments when none exist. The first step is already underway. A Mayo Clinic model detected signs of pancreatic cancer on scans up to three years before diagnosis, when curative treatment may still be possible. A pathology system published in Nature Cancer can recognize cancers across different organs and hospitals from only a handful of example slides, without being retrained for each task. And the first randomized trial of AI-supported mammography, involving more than 100,000 women in Sweden, detected more cancers while cutting radiologists' screen-reading workload by 44%. It also had 12% fewer cancers diagnosed between screening rounds, with a radiologist still reading every mammogram.
These advances are not yet personalized treatment, but they are a necessary first step: seeing more clearly what is happening in each patient. From there, AI can help match patients to therapies that fit their biology, rather than relying on what worked best for the general population. For families facing a rare or atypical diagnosis, that shift cannot come soon enough. The technology is not without risks, and its dangers are real, but its potential to uplift humanity is equally real. In medicine, that potential is measured in lives extended and suffering avoided.
6
